If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
After completion of this reaction, glutathione reductase recycles oxidized glutathione back to the reduced form so that it again can be picked up by GSTs. This glutathione system acts as the major reduction-oxidation buffer in aerobic bacterial cells, contributing to the overall reduced cellular environment of the cytosol.
==== MeSH E05.318.760 – epidemiologic study characteristics ==== MeSH E05.318.760.500 – epidemiologic studies MeSH E05.318.760.500.500 – case-control studies MeSH E05.318.760.500.500.500 – retrospective studies MeSH E05.318.760.500.750 – cohort studies MeSH E05.318.760.500.750.500 – longitudinal studies MeSH E05.318.760.500.750.500.350 – follow-up studies MeSH E05.318.760.500.750.500.650 – prospective studies MeSH E05.318.760.500.875 – cross-sectional studies MeSH E05.318.760.500.950 – seroepidemiologic studies MeSH E05.318.760.500.950.375 – hiv seroprevalence MeSH E05.318.760.535 – clinical trials MeSH E05.318.760.535.200 – clinical trials, phase i MeSH E05.318.760.535.210 – clinical trials, phase ii MeSH E05.318.760.535.220 – clinical trials, phase iii MeSH E05.318.760.535.230 – clinical trials, phase iv MeSH E05.318.760.535.365 – controlled clinical trials MeSH E05.318.760.535.365.500 – randomized controlled trials MeSH E05.318.760.535.500 – multicenter studies MeSH E05.318.760.550 – feasibility studies MeSH E05.318.760.565 – intervention studies MeSH E05.318.760.750 – pilot projects MeSH E05.318.760.875 – sampling studies MeSH E05.318.760.900 – twin studies
pain, redness, or swelling at the injection site; vancomycin flushing syndrome (VFS), previously known as red man syndrome (or "redman syndrome"); thrombophlebitis, which is common when administered through peripheral catheters but not when central venous catheters are used, although central venous catheters are a predisposing factor for upper-extremity deep-vein thrombosis. Damage to the kidneys (nephrotoxicity) and to the hearing (ototoxicity) were side effects of the early, impure versions of vancomycin, and were prominent in clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found nephrotoxicity is an infrequent adverse effect (0.1% to 1% of patients), but this is accentuated in the presence of aminoglycosides. Rare adverse effects associated with intravenous vancomycin (<0.1% of patients) include anaphylaxis, toxic epidermal necrolysis, erythema multiforme, superinfection, thrombocytopenia, neutropenia, leukopenia, tinnitus, dizziness and/or ototoxicity, and DRESS syndrome. Vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura. Historically, vancomycin has been considered a nephrotoxic and ototoxic drug, based on numerous case reports in the medical literature following initial approval by the FDA in 1958. But as its use increased with the spread of MRSA beginning in the 1970s, toxicity risks were reassessed.
Hydromorphone is a semi-synthetic μ-opioid agonist. As a hydrogenated ketone of morphine, it shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, and increased pinpoint constriction of the pupils.
Sources: en.wikipedia.org
=== December === December 1 – COVID-19 pandemic: In California, the first case of Omicron variant, a highly mutated variant of COVID-19, is reported by the CDC in a San Francisco resident, who had traveled to South Africa. December 2 Major League Baseball begins a lockout of its players. It is their first lockout since 1990. COVID-19 pandemic: Minnesota reports their first case of Omicron variant. Two Georgia election officials, Ruby Freeman and Wandrea' ArShaye Moss, file a defamation lawsuit against The Gateway Pundit. The lawsuit is the first to be filed by individual election workers who were targeted during the 2020 presidential election. December 4 – Chris Cuomo is fired by CNN for his violations of journalistic ethics by aiding his scandal-ridden brother. December 9 Workers at a Starbucks in Buffalo, New York vote 19–8 to unionize, becoming the first Starbucks in the country to do so. A virtual summit, Summit for Democracy, was hosted by the United States "to renew democracy at home and confront autocracies abroad". December 10 – A late season tornado outbreak occurs in the Southern and Midwestern United States, causing major damage and killing at least 94 people. December 11 COVID-19 pandemic: North Carolina reports its first case of the Omicron variant in a student at UNC Charlotte. The MLS Cup 2021 hosted in Portland, Oregon, New York City FC defeated Portland Timbers after won 4–2 on penalties (Both teams drew 1–1 in regulation and extra time).
=== Induced resistance === Induced resistance is another mechanism that algae develop to defend against algicidal bacteria. One example, Chaetoceros didymus, was found to be resistant to the algicidal bacterium Kordia algicida by producing its own proteases. These proteases are believed to counteract the lytic enzymes produced by the bacteria. Such a resistance response can be triggered not only by direct contact with bacteria but also by chemical signals present in bacterial culture filtrates.
== Research directions == Research into the mechanism of HD is focused on identifying the functioning of Htt, how mHtt differs or interferes with it, and the brain pathology that the disease produces. Research is conducted using in vitro methods, genetically modified animals, (also called transgenic animal models), and human volunteers. Animal models are critical for understanding the fundamental mechanisms causing the disease, and for supporting the early stages of drug development. The identification of the causative gene has enabled the development of many genetically modified organisms including nematodes (roundworms), Drosophila fruit flies, and genetically modified mammals including mice, rats, sheep, pigs and monkeys that express mutant huntingtin and develop progressive neurodegeneration and HD-like symptoms. Research is being conducted using many approaches to either prevent HD or slow its progression. Disease-modifying strategies can be broadly grouped into three categories: reducing the level of the mutant huntingtin protein (including gene splicing and gene silencing); approaches aimed at improving neuronal survival by reducing the harm caused by the protein to specific cellular pathways and mechanisms (including protein homeostasis and histone deacetylase inhibition); and strategies to replace lost neurons. In addition, novel therapies to improve brain functioning are under development; these seek to produce symptomatic rather than disease-modifying therapies, and include phosphodiesterase inhibitors.
Those peptides expressing a drug-related, non-self epitope on one of their various HLA protein forms (HLA-A, HLA-B, HLA-C, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, or HLA-DR) can bind to a T-cell receptor and thereby stimulate the receptor-bearing parent T cell to initiate attacks on self tissues. Alternatively, a drug or its metabolite may stimulate these T cells by inserting into the groove on a HLA protein to serve as a non-self epitope or bind outside of this groove to alter a HLA protein so that it forms a non-self epitope. In all these cases, however, a non-self epitope must bind to a specific HLA serotype (i.e. variation) in order to stimulate T cells. Since the human population expresses some 13,000 different HLA serotypes while an individual expresses only a fraction of them and since a SJS-inducing drug or metabolite interacts with only one or a few HLA serotypes, a drug's ability to induce SCARs is limited to those individuals who express HLA serotypes targeted by the drug or its metabolite. Accordingly, only rare individuals are predisposed to develop a SCARs in response to a particular drug on the bases of their expression of HLA serotypes: Studies have identified several HLA serotypes associated with development of SJS, SJS/TEN, or TEN in response to certain drugs. In general, these associations are restricted to the cited populations. In some East Asian populations studied (Han Chinese and Thai), carbamazepine- and phenytoin-induced SJS is strongly associated with HLA-B*1502 (HLA-B75), an HLA-B serotype of the broader serotype HLA-B15.
=== Philanthropy === Morea serves as the captain and midfielder of the All Stars Football Club, a celebrity football team that participates in matches to raise funds for charitable causes. He played in a high-profile charity cricket match organized by the IIFA Foundation at Headingley Carnegie Stadium in Leeds, England, on 8 June 2007. The event featured a star-studded Indian celebrity team—including Virat Kohli, Kapil Dev, Vivek Oberoi, Ajay Devgn, Shilpa Shetty, Sunny Deol, and many others—competing against a UK celebrity team and the match benefited the IIFA Foundation's charitable causes. Morea attended a charity football match for the Salman Khan's Being Human Foundation in Mumbai on 15 August 2009. Dino joined Salman Khan, Aamir Khan, Amitabh Bachchan, and others for a blood donation camp in Bandra, Mumbai on 15 August 2010. In March 2013, he participated in a match to support the Magic Funds Organisation, which works with underprivileged children. In 2016, he became associated with Pet Fed, an event platform for pets, joining as an investor and supporter.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.